Successful Medical Adrenalectomy With Amino-glutethimide: Role of Altered Drug Metabolism

Richard J. Santen, Allan Lipton, John Kendall

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

We used amino-glutethimide and dexamethasone in patients with carcinoma of the breast to abolish adrenal steroidogenesis. Initial studies with this approach, however, did not result in complete adrenal suppression and suggested the possibility of accelerated dexamethasone metabolism. The observation of a twofold reduction in H dexamethasone half-life during amino-glutethimide therapy confirmed this hypothesis. Larger doses of dexamethasone (1.5 to 3.0 mg/day) were administered to 22 patients receiving 1 to 2 gm of amino-glutethimide daily to compensate for rapid dexamethasone metabolism. Complete adrenal suppression for as long as 19 months was then observed, with objective tumor regression in eight subjects and relief of bone pain in three others without producing cushingoid side effects.

Original languageEnglish (US)
Pages (from-to)1661-1665
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume230
Issue number12
DOIs
StatePublished - Dec 23 1974

Fingerprint

Glutethimide
Adrenalectomy
Dexamethasone
Pharmaceutical Preparations
Half-Life
Observation
Breast Neoplasms
Bone and Bones
Pain
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{ebe9b9b1b1174909ad94ad91d0d4f22b,
title = "Successful Medical Adrenalectomy With Amino-glutethimide: Role of Altered Drug Metabolism",
abstract = "We used amino-glutethimide and dexamethasone in patients with carcinoma of the breast to abolish adrenal steroidogenesis. Initial studies with this approach, however, did not result in complete adrenal suppression and suggested the possibility of accelerated dexamethasone metabolism. The observation of a twofold reduction in H dexamethasone half-life during amino-glutethimide therapy confirmed this hypothesis. Larger doses of dexamethasone (1.5 to 3.0 mg/day) were administered to 22 patients receiving 1 to 2 gm of amino-glutethimide daily to compensate for rapid dexamethasone metabolism. Complete adrenal suppression for as long as 19 months was then observed, with objective tumor regression in eight subjects and relief of bone pain in three others without producing cushingoid side effects.",
author = "Santen, {Richard J.} and Allan Lipton and John Kendall",
year = "1974",
month = "12",
day = "23",
doi = "10.1001/jama.1974.03240120029015",
language = "English (US)",
volume = "230",
pages = "1661--1665",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "12",

}

Successful Medical Adrenalectomy With Amino-glutethimide : Role of Altered Drug Metabolism. / Santen, Richard J.; Lipton, Allan; Kendall, John.

In: JAMA: The Journal of the American Medical Association, Vol. 230, No. 12, 23.12.1974, p. 1661-1665.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Successful Medical Adrenalectomy With Amino-glutethimide

T2 - Role of Altered Drug Metabolism

AU - Santen, Richard J.

AU - Lipton, Allan

AU - Kendall, John

PY - 1974/12/23

Y1 - 1974/12/23

N2 - We used amino-glutethimide and dexamethasone in patients with carcinoma of the breast to abolish adrenal steroidogenesis. Initial studies with this approach, however, did not result in complete adrenal suppression and suggested the possibility of accelerated dexamethasone metabolism. The observation of a twofold reduction in H dexamethasone half-life during amino-glutethimide therapy confirmed this hypothesis. Larger doses of dexamethasone (1.5 to 3.0 mg/day) were administered to 22 patients receiving 1 to 2 gm of amino-glutethimide daily to compensate for rapid dexamethasone metabolism. Complete adrenal suppression for as long as 19 months was then observed, with objective tumor regression in eight subjects and relief of bone pain in three others without producing cushingoid side effects.

AB - We used amino-glutethimide and dexamethasone in patients with carcinoma of the breast to abolish adrenal steroidogenesis. Initial studies with this approach, however, did not result in complete adrenal suppression and suggested the possibility of accelerated dexamethasone metabolism. The observation of a twofold reduction in H dexamethasone half-life during amino-glutethimide therapy confirmed this hypothesis. Larger doses of dexamethasone (1.5 to 3.0 mg/day) were administered to 22 patients receiving 1 to 2 gm of amino-glutethimide daily to compensate for rapid dexamethasone metabolism. Complete adrenal suppression for as long as 19 months was then observed, with objective tumor regression in eight subjects and relief of bone pain in three others without producing cushingoid side effects.

UR - http://www.scopus.com/inward/record.url?scp=0016144225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016144225&partnerID=8YFLogxK

U2 - 10.1001/jama.1974.03240120029015

DO - 10.1001/jama.1974.03240120029015

M3 - Article

C2 - 4373589

AN - SCOPUS:0016144225

VL - 230

SP - 1661

EP - 1665

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 12

ER -